XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash provided by (used for) operating activities    
Net income (loss) $ 558 $ 946
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal 0 48
Depreciation and amortization 842 803
Deferred and prepaid income taxes (70) (49)
Stock-based compensation expense 165 145
Goodwill and other intangible asset impairment charges 132 173
Net loss (gain) on investments and notes receivable 46 (208)
Contingent consideration net expense (benefit) 68 (117)
Inventory step-up amortization 32 15
Gain (Loss) on Extinguishment of Debt 194 0
Other, net 92 48
Trade accounts receivable (176) (131)
Inventories (275) (315)
Other assets (298) (145)
Accounts payable, accrued expenses and other liabilities (590) 275
Cash provided by (used for) operating activities 719 1,392
Investing activities:    
Purchases of property, plant and equipment and internal use software (376) (288)
Proceeds from sale of property, plant and equipment 10 10
Payments for acquisitions of businesses, net of cash acquired (1,542) (2,014)
Proceeds from royalty rights 54 62
Payments for Hedge, Investing Activities 56 15
Proceeds from disposal of certain businesses and assets 5 801
Proceeds from (payments for) investments and acquisitions of certain technologies (36) 279
Cash provided by (used for) investing activities (1,828) (1,136)
Financing activities:    
Payment of contingent consideration previously established in purchase accounting (335) (14)
Payments for royalty rights (75) (85)
Payments on short-term borrowings (250) 0
Net increase (decrease) in commercial paper (1) 0
Payments on long-term borrowings and debt extinguishment costs (3,184) 0
Proceeds from long-term borrowings, net of debt issuance costs 3,270 0
Cash dividends paid on preferred stock (42) (42)
Cash used to net share settle employee equity awards (49) (48)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans 117 102
Cash provided by (used for) financing activities (549) (87)
Effect of foreign exchange rates on cash (12) (5)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents (1,671) 164
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 2,168 1,995
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period 497 2,159
Supplemental Information    
Stock-based compensation expense 165 145
Fair value of contingent consideration recorded in purchase accounting 0 384
Non-cash impact of transferred royalty rights $ (54) $ (62)